Gastrointestinal Cancer | Specialty

Dr. Overman on Remaining Questions With Immunotherapy in CRC

February 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the remaining questions with immunotherapy in colorectal cancer.

Dr. Pishvaian on the Future of Entrectinib in Pancreatic Cancer

February 20th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of entrectinib in the treatment of patients with pancreatic cancer.

Dr. Andre Discusses the Future of Immunotherapy in mCRC

February 20th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the future of immunotherapy for patients with metastatic colorectal cancer.

Biomarkers and Novel Approaches in CRC

February 17th 2018

Reverce Study: Outcomes and Impact

February 17th 2018

Sequencing of Therapy in Refractory mCRC

February 17th 2018

Management of Side Effects With TAS-102

February 17th 2018

Proactive Side Effect Management With Regorafenib

February 17th 2018

Clinical Implications of the ReDOS Findings

February 17th 2018

The Regorafenib Dose Optimization Study

February 17th 2018

Treatment Options in Refractory mCRC

February 17th 2018

Treatment Goals in Refractory mCRC

February 17th 2018

Expert Highlights Promising Research in mCRC and Other GI Cancers

February 17th 2018

Michael A. Morse, MD, discusses key trials that have broadened the treatment landscape of mCRC, and other ongoing developments in gastrointestinal cancers.

Lilly's Unique Reception Helps Attendees Step Into the Minds of People Living With GI Cancers

February 15th 2018

Lilly hosted an immersive and interactive reception during the 2018 Gastrointestinal Cancers Symposium entitled,

Dr. Kudo Discusses TACE Plus Sorafenib in HCC

February 15th 2018

Masatoshi Kudo, MD, PhD, Department of Gastroenterology and Hepatology, Kindai University, discusses the randomized phase II trial comparing transarterial chemoradiation (TACE) plus sorafenib (Nexavar) with TACE alone in patients with hepatocellular carcinoma (HCC).

Dr. Bekaii-Saab on the Importance of the ReDOS Study in mCRC

February 14th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the importance of the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer (mCRC).

Dr. Morse on Managing Toxicities and Sequencing Agents in mCRC

February 12th 2018

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, discusses factors that should be taken into consideration when sequencing agents in metastatic colorectal cancer.

Dr. Marshall on the Importance of Testing for BRAF Mutations in mCRC

February 12th 2018

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the specificity now required in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Jarnagin on the Improvements in Surgery for Patients With mCRC

February 12th 2018

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.

Dr. Chau on Findings of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer

February 9th 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses finding with the combination of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.